Highnoon Laboratories (HINOON)
29 stories published on HINOON since September 2025. See all coverage.
News sentiment trend
Counts of positive, neutral, and negative news items over the last 90 days. Not a price chart.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Sentiment timeline
How news sentiment on Highnoon Laboratories (HINOON) has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
Why this reading
The recent items weighing most on this reading, by direction and influence.
FY27 Budget Continues Tariff Reforms: Auto, Pharma, Steel, Chemical Stocks See Input Cost Relief
Budget taxation (GST/FED/duties) · Medium influence · Long term
Barcode System on Medicines and Pak-China Pharma Conference: Positive for Pharma Stocks
Direct news · Medium influence · Long term
Punjab's Rs18.5 Billion Free Treatment Program Boosts Pharmaceutical Sector
Consumer demand & purchasing power · Medium influence · Long term
DRAP to Tighten Drug Pricing Rules: Pakistan Pharma Stocks in Focus
Drug pricing (DRAP) · Low influence · Long term
52 New Life-Saving Medicine Prices Approved: Pharma Stocks in Focus
Drug pricing (DRAP) · Low influence · Long term
Direct news
The most recent stories naming HINOON directly, across all of our coverage.
Barcode System on Medicines and Pak-China Pharma Conference: Positive for Pharma Stocks
Budget Removes Tax on Sanitary Products, Contraceptives: Consumer and Pharma Stocks May Benefit
Soaring Drug Prices in KP: Positive for Pakistan Pharma Stocks
Pakistan Pharma Profits Hit Record Rs42 Billion in 2025 on Deregulation: Searle, Abbott, AGP, Highnoon
Taliban Ban on Pakistani Drug Imports: Pharmaceutical Stocks Face Export Headwind
Pak-Uzbek Body to Boost Pharma Trade: Opportunities for Pakistani Drugmakers
Indirect drivers in the news
Macro, commodity, FX and regulatory forces that have moved HINOON, with the stories behind each.
See the full picture
Sign up free to track HINOON, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track HINOON for freeInformational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.